Institute for Advanced Chemistry of Catalonia (IQAC-CSIC), Jordi Girona 18-26, E-08034 Barcelona, Spain.
Networking Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), E-08034 Barcelona, Spain.
Molecules. 2022 Jun 20;27(12):3944. doi: 10.3390/molecules27123944.
The development of oligonucleotide conjugates for in vivo targeting is one of the most exciting areas for oligonucleotide therapeutics. A major breakthrough in this field was the development of multifunctional GalNAc-oligonucleotides with high affinity to asialoglycoprotein receptors (ASGPR) that directed therapeutic oligonucleotides to hepatocytes. In the present study, we explore the use of G-rich sequences functionalized with one unit of GalNAc at the 3'-end for the formation of tetrameric GalNAc nanostructures upon formation of a parallel G-quadruplex. These compounds are expected to facilitate the synthetic protocols by providing the multifunctionality needed for the binding to ASGPR. To this end, several G-rich oligonucleotides carrying a TGGGGGGT sequence at the 3'-end functionalized with one molecule of -acetylgalactosamine (GalNAc) were synthesized together with appropriate control sequences. The formation of a self-assembled parallel G-quadruplex was confirmed through various biophysical techniques such as circular dichroism, nuclear magnetic resonance, polyacrylamide electrophoresis and denaturation curves. Binding experiments to ASGPR show that the size and the relative position of the therapeutic cargo are critical for the binding of these nanostructures. The biological properties of the resulting parallel G-quadruplex were evaluated demonstrating the absence of the toxicity in cell lines. The internalization preferences of GalNAc-quadruplexes to hepatic cells were also demonstrated as well as the enhancement of the luciferase inhibition using the luciferase assay in HepG2 cell lines versus HeLa cells. All together, we demonstrate that tetramerization of G-rich oligonucleotide is a novel and simple route to obtain the beneficial effects of multivalent -acetylgalactosamine functionalization.
寡核苷酸缀合物的体内靶向发展是寡核苷酸治疗学最令人兴奋的领域之一。该领域的一个重大突破是开发了具有高亲和力的多功能 GalNAc-寡核苷酸,这些寡核苷酸与去唾液酸糖蛋白受体 (ASGPR) 结合,将治疗性寡核苷酸靶向肝细胞。在本研究中,我们探索了在形成平行 G-四链体时,在 3'端用一个 GalNAc 单位功能化的富含 G 的序列形成四聚体 GalNAc 纳米结构的用途。这些化合物有望通过提供与 ASGPR 结合所需的多功能性来简化合成方案。为此,合成了几种在 3'端带有 TGGGGGGT 序列并在其 3'端带有一个乙酰半乳糖胺 (GalNAc) 分子的富含 G 的寡核苷酸,以及适当的对照序列。通过圆二色性、核磁共振、聚丙烯酰胺电泳和变性曲线等各种生物物理技术证实了自组装平行 G-四链体的形成。与 ASGPR 的结合实验表明,治疗货物的大小和相对位置对于这些纳米结构的结合至关重要。评估了所得平行 G-四链体的生物学特性,证明了这些结构没有毒性。还证明了 GalNAc-四链体对肝细胞的内化偏好,以及在 HepG2 细胞系中与 HeLa 细胞相比,使用荧光素酶测定法增强了荧光素酶抑制作用。总之,我们证明了富含 G 的寡核苷酸的四聚化是获得多价乙酰半乳糖胺功能化的有益效果的一种新的简单途径。